Table 3.
FDA-Approved PEGylated Drugs#
| Product | Trade Name | PEGylated Molecule | PEG Size (kDa) | Disease | Approval Year | Company |
|---|---|---|---|---|---|---|
| PEGadamase | Adagen® | Adenosine deaminase | 5 | Immunodeficiency | 1990 | Enzon |
| PEGaspargase | Oscarpar® | L-asparaginase | 5 | Leukemia | 1994 | Enzon |
| PEGinterferon-α2b | PEG-Intron® | Interferon-α2b | 12 | Hepatitis C | 2000 | Schering-Plough/Enzon |
| PEGinterferon-α2a | Pegasys® | Interferon-α2a | 20 | Hepatitis C | 2001 | Hoffmann-La Roche |
| PEGfilgrastim | Neulasta® | filgrastim | 20 | Neutropenia | 2002 | Amgen |
| PEGvisomant | Somavert® | Growth hormone antagonist | 5 | Acromegaly | 2003 | Pfizer |
| PEGaptanib | Macugen® | Anti-EVGF aptamer | 20 | Macular degeneration | 2004 | Pfizer |
| Doxorubicin HCl liposome | Doxil/Caely® | Liposome of doxorubicin | 2 | Cancer | 2005 | Ortho Biotech/ Schering-Plough |
| Epoetin beta-methoxy PEG | Mircera® | Erythropoietin-beta | 30 | Anemia | 2007 | Roche |
| PEG-Certolizumab pegol | Cimzia® | Tumor necrosis factor inhibitor | 20 | Rheumatoid arthritis and Crohn’s | 2008 | Nektar/UCB Pharma |
| PEGloticase | Krystexxa® | Uricase | 10 | Gout | 2010 | Savient Pharma |
| PEGinesatide | Omontys® | dimeric peptide | 40 | Anemia | 2012 | Affymax/Takeda Pharmaceuticals |
| PEGinterferon β1a | Plegridy® | interferon β1a | 12 | Multiple sclerosis | 2014 | Biogen |
| Naloxegol | Movantik® | opioid | 0.34 | Opioid-induced constipation | 2014 | AstraZeneca |
| PEG-growth hormone | Jintrolong® | growth hormone | 40 | Growth deficiency | 2014 | GeneScience |
| PEG-antihemophilic Factor VIII | Adynovate® | Coagulation factor (VIII) | ~2 | hemophilia A | 2015 | Baxalta |
| Nonacog β pegol | Rebinyn® | Coagulation factor (IX) | 40 | hemophilia B | 2017 | Novo Dordisk |
| Pegvaliase | Biomarin® | phenylalanineNH3-lyase | 20 | Phenylketonuria | 2018 | BioMarin Pharmaceutica |
Note: #All data from publicly available sources.